









Markets
/
Stocks
/
nasdaq-vnrx
/

VolitionRX Ltd

VNRX

0.680USD

+0.056+8.96%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

70.71MMarket Cap

LossP/E TTM



VolitionRX Ltd

0.680

+0.056+8.96%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

148 / 506

Overall Ranking

257 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.375

Target Price

+440.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 302.59% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.23M.

Undervalued

The company’s latest PE is -2.80, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 41.39M shares, increasing 2.04% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.64, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 406.69K, representing a year-over-year increase of 2.75%, while its net profit experienced a year-over-year increase of 10.04%.

Score

Industry at a Glance

Previous score

6.64

Change



Financials

5.02

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.99

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.45

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.57, which is -31.18% below the recent high of -1.77 and -2.81% above the recent low of -2.64.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 148/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.60, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for VolitionRX Ltd is 3.00, with a high of 5.00 and a low of 2.50.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.375

Target Price

+440.78%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

VolitionRX Ltd

VNRX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.26, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 0.71 and the support level at 0.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.26

Change

0.5

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.006

Neutral

RSI(14)

55.716

Neutral

STOCH(KDJ)(9,3,3)

72.024

Buy

ATR(14)

0.048

Low Volatility

CCI(14)

66.820

Neutral

Williams %R

31.028

Buy

TRIX(12,20)

-0.232

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

0.640

Buy

MA10

0.635

Buy

MA20

0.648

Buy

MA50

0.666

Buy

MA100

0.630

Buy

MA200

0.605

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cotterford Co., Ltd.

12.01M

Lagoda Investment Management, L.P.

10.19M

+34.56%

Armistice Capital LLC

8.21M

-3.25%

Innes (Guy Archibald)

2.81M

+0.72%

Reynolds (Cameron John)

1.88M

+0.67%

The Vanguard Group, Inc.

Star Investors

706.06K

+10.90%

Concord International Inc.

1.01M

Geode Capital Management, L.L.C.

761.95K

+2.43%

Micallef (Jacob Vincent)

456.18K

-4.51%

BlackRock Institutional Trust Company, N.A.

445.19K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.23, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.27. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.